

Applicant: Pero, et al.
Title: Use of Combretastatin A-4 and Its Prodrugs as an Immune
Enhancing Therapy
Appl. No.: 10/034746
Filing Date: 26-Dec-2001
Examiner: GUZO, David
Art Unit: 1636
Confirmation 1899
Number:

REVOCATION AND NEW POWER OF ATTORNEY BY ASSIGNEE

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

OXiGENE, Inc. and Bristol-Myers Squibb Company are the assignees of the entire right, title and interest in United States Patent Application Serial Number 10/034746 by virtue of an assignment from the inventors recorded in the United States Patent and Trademark Office at Reel/Frame 012705/0369, 012708/0723, 012966/0931, and 012966/0301.

OXiGENE, Inc. and Bristol-Myers Squibb Company, through their duly-delegated representatives, hereby revoke all prior Powers of Attorney submitted in this application, and hereby appoint the registered patent attorneys and patent agents associated with Customer Number:

75605

as their principal attorneys to have full power to prosecute this application and any continuations, divisions, reissues and reexaminations thereof, to receive the patent, to transact all business in the United State Patent and Trademark Office connected

therewith, and to have full power of substitution, association, and revocation, including the power to revoke the power of attorney of any associate attorney.

Please direct all future correspondence concerning this application to:

Karen E. Flick
OXiGENE, Inc.
Customer Number: 75605

Telephone: (650) 284-5575
Facsimile: (650) 284-5596

Executed this ____th day of _____, 2008.

OXiGENE, Inc.

By:


(Signature)

James B. Murphy
Vice President and Chief Financial Officer

Executed this 14th day of August, 2008.

Bristol-Myers Squibb Company

By:



(Signature)

Anastasia P. Winslow

(Printed Name)

Senior Patent Counsel

(Title)